Insulet (PODD) Cash from Financing Activities (2010 - 2026)
Insulet (PODD) posted Cash from Financing Activities of -$319.9 million for Q1 2026, down 341.24% on a QoQ basis from -$72.5 million in Q4 2025, and down 215.2% year-over-year from $277.7 million in Q1 2025.
Insulet (PODD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Insulet's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$319.9 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 215.2% year-over-year to -$319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 552.2% YoY) and the FY2025 annual result came in at -$595.3 million, down 2026.07% from the prior year.
- Cash from Financing Activities was -$319.9 million for Q1 2026 at Insulet, down from -$72.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $277.7 million in Q1 2025 and bottomed at -$457.0 million in Q3 2025.
- A 5-year average of -$58.7 million and a median of -$12.1 million in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 2069.5% in 2025, while the deepest fall reached 23952.63% in 2025.
- Insulet's Cash from Financing Activities stood at -$14.5 million in 2022, then jumped by 115.17% to $2.2 million in 2023, then sank by 1045.45% to -$20.8 million in 2024, then tumbled by 248.56% to -$72.5 million in 2025, then plunged by 341.24% to -$319.9 million in 2026.
- Business Quant data shows PODD's Cash from Financing Activities at -$319.9 million in Q1 2026, -$72.5 million in Q4 2025, and -$457.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -319.90 Mn |
| Mar 31, 2026 | -319.90 Mn |
| Dec 31, 2025 | -72.50 Mn |
| Dec 31, 2025 | -72.50 Mn |
| Sep 30, 2025 | -457.00 Mn |
| Sep 30, 2025 | -457.00 Mn |
| Jun 30, 2025 | -343.50 Mn |
| Jun 30, 2025 | -343.50 Mn |
| Mar 31, 2025 | 277.70 Mn |
| Mar 31, 2025 | 277.70 Mn |
| Dec 31, 2024 | -20.80 Mn |
| Dec 31, 2024 | -20.80 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |